This body of evidence lends ground to the design of mAb combination strategies [168,171,172,173] and to the generation of bispecific molecules that associate a tumor-specific scFv with cognate ligands for either NKG2D or NKp30, and that synergistically augment ADCC [174]. The gene discussed is KLRK1; the disease is neoplasm.